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        Viral proteins are intracellularly degraded into 
small peptides and then loaded on MHC class I 
molecules, which are presented on the surface 
of infected cells. These peptide  –  MHC class I 
complexes serve as physiologic ligands for the 
TCR and, upon TCR engagement, trigger sev-
eral lymphocyte eff  ector functions. In addi-
tion, peptide –  MHC class I complexes also serve 
as ligands for several alternative receptors, such 
as the killer-Ig receptors (KIRs) expressed on 
NK and T cells ( 1  ) or the Ig-like transcript (ILT) 
receptors predominantly expressed either on T 
cells (ILT2/leukocyte Ig receptor [LIR]1) ( 2, 3 ) 
or on macrophages, monocytes, and DCs (ILT4/
LIR2) (  4, 5  ). Binding of peptide  –  MHC class I 
complexes to KIRs (  6  ) or ILT2 (  7  –  9  ) receptors 
results in an impairment of lymphocyte eff  ec-
tor functions, such as cytotoxic properties or 
cytokine secretion capacities, whereas bind-
ing to ILT4 can lead to the transformation of 
macrophages and DCs into tolerogenic cells with 
lower expression of co-stimulatory molecules 
and ineff  ective antigen-presenting characteris-
tics (  10, 11  ). 
  A series of recent studies has shown that 
HIV-1 can use its extraordinary genetic plastic-
ity to evade host immune surveillance (  12  –  19  ). 
This has been demonstrated particularly clearly 
in the context of CD8  +   T cell responses, in 
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  Viral mutational escape can reduce or abrogate recognition by the T cell receptor (TCR) of 
virus-specifi  c CD8  +   T cells. However, very little is known about the impact of cytotoxic 
T lymphocyte (CTL) epitope mutations on interactions between peptide–major histocompat-
ibility complex (MHC) class I complexes and MHC class I receptors expressed on other cell 
types. Here, we analyzed a variant of the immunodominant human leukocyte antigen 
(HLA)-B2705  –  restricted HIV-1 Gag KK10 epitope (KRWIILGLNK) with an L to M amino 
acid substitution at position 6 (L6M), which arises as a CTL escape variant after primary 
infection but is suffi  ciently immunogenic to elicit a secondary, de novo HIV-1  –  specifi  c 
CD8  +   T cell response with an alternative TCR repertoire in chronic infection. In addition to 
altering recognition by HIV-1  –  specifi  c CD8  +   T cells, the HLA-B2705  –  KK10 L6M complex 
also exhibits substantially increased binding to the immunoglobulin-like transcript (ILT) 
receptor 4, an inhibitory MHC class I  –  specifi  c receptor expressed on myelomonocytic cells. 
Binding of the B2705  –  KK10 L6M complex to ILT4 leads to a tolerogenic phenotype of 
myelomonocytic cells with lower surface expression of dendritic cell (DC) maturation 
markers and co-stimulatory molecules. These data suggest a link between CTL-driven 
mutational escape, altered recognition by innate MHC class I receptors on myelomonocytic 
cells, and functional impairment of DCs, and thus provide important new insight into 
biological consequences of viral sequence diversifi  cation. 2814 DIFFERENTIAL RECOGNITION OF CTL EPITOPE VARIANTS BY ILT4 | Lichterfeld et al.
strong CD8  +   T cell response against the KK10 WT peptide 
that was present in their autologous viral sequence, as deter-
mined by population viral sequencing. Using interferon      
ELISPOT assays, we found that in addition to the KK10 WT 
peptide, KK10 variants with amino acid substitutions at posi-
tion 2 (R2K or R2T) were still recognized by CD8  +   T cells 
during primary infection, although the avidity of recognition 
decreased by     10-fold and might be weaker when the vari-
ant peptide is naturally presented (  Fig. 1  ) (  29  ).   In contrast, the 
KK10 L6M variant and the variants with combined muta-
tions at position 2 and 6 (R2K/L6M, R2T/L6M) were only 
very poorly recognized during primary HIV-1 infection com-
pared with either the KK10 WT sequence or the KK10 vari-
ants with amino acid changes at position 2 only (  Fig. 1  ). Thus, 
these data show a relative lack of recognition of the KK10 
L6M variant in primary infection and suggest that the sub-
sequent emergence of this viral mutation results from CD8  +   
T cell  –  mediated immune pressure. 
  De novo CD8  +   T cell response against the KK10 L6M variant 
during chronic HIV-1 infection 
  In three of the above-mentioned individuals, we had the op-
portunity to longitudinally analyze the evolution of the KK10 
epitope after primary infection in the absence of antiretroviral 
treatment. In these longitudinal studies, we found that all 
three individuals developed the KK10 L6M mutation in the 
autologous viruses during the subsequent disease process, most 
likely resulting from the relative lack of recognition of this 
variant by the primarily mounted KK10-specifi  c CD8  +   T 
which highly specifi  c interactions between the peptide –  MHC 
class I complex and the TCR can be aff  ected by single amino 
acid variations in the antigenic peptide that reduce peptide 
binding to the restricting MHC molecule (  12, 15  ), interfere 
with recognition by TCR contact residues (  16, 20  ), or pre-
vent intracellular peptide processing (  21, 22  ). The inter-
actions of peptide  –  MHC class I complexes with KIRs are 
believed to be also dependent on the sequence of the pre-
sented antigenic peptide (  23  –  26  ). However, although artifi  -
cial single amino acid changes in antigenic peptides can lead 
to a diff  erential recognition by KIRs and may thus modify 
their inhibitory properties (  27  ), evidence for a selection of 
HIV-1 mutational CTL escape variants aff  ecting KIR recog-
nition is currently lacking. The degree to which the binding 
of peptide  –  MHC class I complexes to ILT receptors depends 
on the sequence of the antigenic peptide is currently un-
known, and it is uncertain if HIV-1 mutational escape can 
aff  ect the interaction of peptide  –  MHC class I complexes with 
these receptors. 
  In this study, we performed a detailed analysis of the genetic 
evolution of the HLA-B2705  –  restricted HIV-1 cytotoxic T 
cell epitope KK10 (KRWIILGLNK), which is an extremely 
immunodominant epitope in HLA-B2705 –  expressing HIV-1 – 
infected individuals. We show that a variant of this epitope 
with an L to M substitution at position 6 (L6M) frequently 
arises as a CTL escape variant. Furthermore, our data indicate 
that this mutation increases binding to ILT4 and by this way 
leads to enhanced functional inhibition of DCs. These data 
indicate that viral mutational escape does not only aff  ect rec-
ognition by CD8  +   T cells, but can also create better ligands 
for inhibitory MHC class I receptors on myelomonocytic 
cells, and thus contribute to a tolerogenic functional profi  le 
of these cells. 
    RESULTS   
  Lack of recognition of the KK10 L6M variant by KK10-
specifi  c CD8  +   T cells during primary HIV-1 infection 
  The KK10 epitope is an extremely immunodominant target 
for HIV-1  –  specifi  c CD8  +   T cells in HLA-B2705  –  expressing 
individuals (  28, 29  ) and has been associated with a slower 
HIV-1 disease progression (  30, 31  ). The most frequent HLA-
B2705  –  associated mutation in this epitope involves an L to M 
amino acid substitution at position 6 (L6M), which does not 
substantially aff  ect the binding avidity to the restricting 
HLA molecule (  29  ), peptide processing (  29  ), or viral fi  tness 
(  32  ), but may alter the interaction with TCR contact resi-
dues (  27  ). Mutations at position 2 in this epitope, which typi-
cally occur late during the disease and subsequent to the 
L6M mutation, are also strongly associated with HLA-B2705 
expression and have been shown to reduce binding to HLA-
B2705 (  29  ). 
  To determine if the KK10 L6M variant is associated with 
loss of CD8  +   T cell recognition and thus represents a CTL 
escape variant, we tested the recognition of this variant in six 
HIV-1  –  infected HLA-B2705  +  individuals identifi  ed during 
primary HIV-1 infection. All of these subjects mounted a 
  Figure 1.     Consistent lack of recognition of the KK10 L6M variant 
by KK10-specifi  c CD8  +   T cells during primary HIV-1 infection. 
(A) Cross-reactivity of KK10-specifi  c CD8  +   T cells against KK10 variants 
with amino acid substitutions at positions 2, 6, or 2 and 6 as determined 
by interferon-     ELISPOT with PBMC samples collected during primary infec-
tion. Data from one representative study individual infected with a virus 
harboring the KK10 WT epitope are shown. (B) Recognition of the KK10 
WT and variant peptides by six HIV-1  –  infected individuals during primary 
HIV-1  infection.   JEM VOL. 204, November 26, 2007 
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WT or KK10 L6M peptides. In a total of 10 HLA-B2705    −    
study individuals, no binding of either one of these penta-
mers to NK cells, T cells, or B cells was found, suggesting that 
TCR-independent interactions with lymphocellular MHC 
class I receptors, such as ILT2 or KIRs that were expressed 
in 5  –  15% and 5  –  35% of lymphocytes, respectively (  2, 33  ), 
did not occur. However, in all 10 study subjects, we consis-
tently found that both pentamers were clearly able to bind to 
peripheral blood CD14  +   monocytes and CD11c  +   HLA-DR  +   
lin    −    peripheral blood DCs. Interestingly, the binding of the 
HLA-B2705  –  KK10 L6M pentamer to these leukocellular 
subgroups was between two- and threefold stronger than that 
of the B2705 pentamer refolded with the WT peptide (  Fig. 3, 
A and B  ), although no diff  erence in binding intensity was seen 
between the two pentamers on cross-reactive HLA-B2705  –
  KK10-specifi  c CD8  +   T cell populations (  Fig. 3 A  ).   More in-
tense binding of the B2705  –  KK10 L6M pentamer to CD14  +   
monocytes compared with the B2705/KK10 WT pentamer 
was observed over a wide range of pentamer concentrations 
(  Fig. 3 C  ). Binding of the pentamers to macrophages and 
DCs was abrogated by antibodies blocking ILT4, an inhibi-
tory MHC class I receptor expressed on myelomonocytic 
cells (  Fig. 3 B  ), which is up-regulated in chronic untreated 
HIV-1 infection compared with HIV-1  –  uninfected individ-
uals (  34  ), individuals with acute or primary HIV-1 infection 
(Fig. S1 A, available at http://www.jem.org/cgi/content/
full/jem.20061865/DC1), or individuals with chronic treated 
HIV-1 infection (Fig. S1 B). In contrast, blocking antibodies 
directed against several other MHC class I receptors, including 
cell responses. This switch in the autologous viral KK10 se-
quence was associated with a strong increase in the CD8  +   T cell 
population able to recognize the KK10 L6M variant (  Fig. 2 A  ) 
and the recruitment of an alternative TCR      and      chain 
repertoire (Table I), indicating the de novo generation of a 
KK10 L6M variant-specifi  c CD8  +   T cell response.   The rec-
ognition of the L6M variant in these individuals was at least 
partially mediated by newly generated KK10-specifi  c CD8  +   
T cell clones with cross-reactive TCRs that had almost iden-
tical capacities to recognize the KK10 WT and the KK10 
L6M variant (  Fig. 2 B  ). A strong recognition of the KK10 
L6M variant was also detected by cross-sectional analysis 
of fi  ve additional subjects with chronic HIV-1 infection 
harboring the L6M mutation in their autologous viral se-
quence (  Fig. 2 C  ). Overall, these data show that the KK10 
L6M mutation represents an escape variant from the initially 
recruited TCR repertoire of KK10-specifi  c CD8  +   T cells 
during primary infection, but is suffi   ciently immunogenic 
to elicit a variant-specifi  c de novo CD8  +   T cell response in 
chronic infection. 
  Enhanced binding of the HLA-B2705  –  KK10 L6M complex 
to ILT4 on monocytes and DCs 
  To determine if the L6M mutation in the KK10 epitope, in 
addition to altering binding to the TCR, also aff  ects recogni-
tion by other HLA class I receptors expressed on lymphocytes, 
monocytes/macrophages, or DCs, we stained PBMCs from 
chronically HIV-1  –  infected, treatment-naive, and HLA-B2705    −    
individuals with HLA-B2705 pentamers refolded with the KK10 
  Figure 2.     De novo HIV-1  –  specifi  c CD8  +   T cell responses against the KK10 L6M variant during chronic HIV-1 infection. (A) Intra-individual 
comparison of the recognition of the KK10 WT (left panel) and the KK10 L6M (right panel) variant during primary (KK10 WT sequence in autologous virus) 
and chronic (KK10 L6M variant sequence in autologous virus) HIV-1 infection as measured by interferon-     ELISPOT in three study subjects. (B) Cross-
recognition of the KK10 WT and the KK10 L6M variant by two different KK10-specifi  c CD8  +   T cell clones isolated during chronic HIV-1 infection in the 
respective study individuals as measured by interferon-     ELISPOT. Data from two clones using the indicated TCRs are shown. (C) Recognition of naturally 
occurring KK10 variants in eight study subjects with chronic HIV-1 infection harboring the KK10 L6M variant in their autologous  virus.   2816 DIFFERENTIAL RECOGNITION OF CTL EPITOPE VARIANTS BY ILT4 | Lichterfeld et al.
HLA-B2705  –  KK10 WT complex, we stimulated immature, 
monocyte-derived DCs (MDDCs) with a maturation-induc-
ing cytokine cocktail in the presence or absence of the two 
B2705/KK10 pentamers and measured the ensuing up-regu-
lation of DC maturation surface markers (HLA-DR, CD83, 
CD40, CD80, and CD86). For these experiments, mono-
cyte-derived immature DCs with strongly detectable ILT4 
surface expression were generated by a 5-d ex vivo culture 
with GM-CSF. As shown in   Fig. 4   (A and C), we consis-
tently observed that the up-regulation of such molecules 
was inhibited substantially when cells had been exposed to 
B2705  –  KK10 L6M pentamer complexes, whereas incuba-
tion with the B2705  –  KK10 WT pentamers showed no obvi-
ous inhibitory eff  ect.   
  Because stimulation with L6M pentamers had an inhibi-
tory eff  ect on DC maturation, we subsequently determined 
whether peptide-loaded APCs would have a similar eff  ect. 
Therefore, we generated ILT4-expressing DCs from the PBMCs 
of HIV-1  –  uninfected HLA-B2705  –  expressing donors, which 
were subsequently divided into two populations. The fi  rst 
population (  “  presenters  ”  ) was labeled with CFSE, matured 
with cytokine cocktail, and loaded with KK10 WT or KK10 
L6M peptide, and the second population (  “  responders  ”  ) was 
initially left immature, mixed with the autologous presenters 
for 4 h, and then matured with cytokine cocktail. After 16 h, 
the degree of maturation of the responders was determined 
by fl  ow cytometry, whereas the CFSE-labeled presenters were 
excluded from the analysis. As shown in   Fig. 4 B  , presenter 
cells loaded with the KK10 L6M peptide, but not with KK10 
WT peptide or without peptide, were able to inhibit the up-
regulation of CD86, CD40, and HLA-DR on the responder 
those against ILT2, had no eff  ect on pentamer binding intensity 
to these macrophages or monocytes (not depicted). To con-
fi  rm an antigenic peptide variant  –  specifi  c binding mechanism 
between ILT4 and HLA-B27  –  KK10 complexes, these recep-
tor  –  ligand interactions were further analyzed using recom-
binant proteins (ILT4-IgG dimers and HLA-B2705 KK10 
WT/L6M tetramers) and surface plasmon resonance (SPR) 
experiments. These assays indicated an apparent steady-state 
equilibrium constant (K    D    ) of 122 nM for the binding of the 
HLA-B27  –  KK10 L6M complex to an ILT4 dimer compared 
with a K    D     of 733 nM for the interaction between the WT 
HLA-B27  –  KK10 complex and the ILT4 dimer (  Fig. 3 D  ). 
Although the use of recombinant ILT4 in a dimer form pre-
cludes assessment of the affi   nity between HLA-B2705 and 
naturally occurring, monomeric ILT4, this observation corre-
sponds to a sixfold increase in apparent affi   nity for the inter-
action involving the L6M mutation relative to that of the WT. 
Overall, these data indicate that HLA-B2705 KK10 penta-
mers can bind to myelomonocytic cells via ILT4, and that the 
degree of binding is infl  uenced by the amino acid sequence of 
the bound KK10 peptide. 
  The HLA-B2705  –  KK10 L6M complex leads to ILT4-
mediated functional impairment of DCs 
  Previous data have shown that agonistic ILT4 engagement by 
MHC class I molecules can transform the functional reper-
toire of DCs toward a tolerogenic profi  le with lower ex-
pression of co-stimulatory molecules and a decreased capacity 
for T cell expansion (  10, 11  ). To test if the B2705  –  KK10 
L6M complex preferentially increases the tolerogenic prop-
erties of DCs or myelomonocytic cells in comparison to the 
  Table I.  HLA-B2705 – KK10-specifi  c TCR      and      chain repertoire 
  KK10 WT in autologous virus    KK10 L6M in autologous virus 
Study patient Time TCR      chain TCR      chain Time    a    TCR      chain TCR      chain
1 Day 41 PP n. d.  V    27-CASSQRTGELF-J2.2 (8/11) 
  V    20.1-CSAWTSGGRADTQY-J2.3 (3/11)
Day 760 PP n. d.  V    27-CASRVAEVNYEQY-J2.7 (4/15) 
  V    5.6-CASSYSGSNYEQY-J2.7 (11/15)
2 Day 0 PP V    19-CALGEANTGFQKLV-J8 (2/24) 
  V    19-CAPSEANTGFQKLV-J8 (1/24) 
  V    19-CALSEADTGFQKLV-J8 (1/24) 
  V    19-CALSEANTGFQKLV-J8 (LGTG) (1/24) 
  V    19-CALSEANTGFQKLV-J8 (FETG) (1/24) 
  V    19-CALSEANTGFQKLV-J8 (18/24)
V    5.4-CASSSTAPDTEAF-J1.1-(1/46) 
  V    5.4-CASSGTAPAAEAF-J1.1 (1/46) 
  V    5.4-CASSLTAPDTEAF-J1.1 (32/46) 
  V    27-CASSRSTGELF-J2.2 (10/46) 
  V    20.1-CSARDQRDYQETQY-J2.5 (2/46)
Day 325 PP V    4-CLVVRMDSSYKLI-J12 (4/23) 
  V    4-CLVVWMDSSYKLI-J12 (1/23) 
  V    1.1-CAVQSDYKLS-J20 (6/23) 
  V    5-CAERGLMDTGRRALT-J5 (12/23)
V    6.6-CASSYSRGAGNTIY-J1.3 (1/43) 
  V    28-CASSLKDEQF-J2.1-(1/43) 
  V    24-CATGLPEGSQETQY-J2.5 (1/43) 
  V    19-CASSRRALRGYT-J1.2 (5/43) 
  V    7.2-CASSLGRGNEQF-J2.1-(2/43) 
  V    27-CASSQRTGELF-J2.2 (8/43) 
  V    27-CASSPRTGELF J2.2 (5/43) 
  Vb20.1-CSARETSGAYNEQF J2.1(18/43)
3 Day 21 PP V    8.4-CAVTLLGTGGFKTI-J9 (9/18) 
  V    12.2-CAV NKVEFNAGGTSGKLT-J52 (9/18)
V    7.9-CANSLDGDQPGH-J1.5 (1/24) 
  V    7.9-CASSLDGDQPQH-J1.5 (4/24) 
  V    7.9-CASSLDRDEQF-J2.1 (1/24) 
  V    27-CASSKNQWEQY-J2.7 (7/24) 
  V    27-CASSPTSYEQY-J2.7 (1/24) 
  V    9-CASSSFDRANEQF-J2.1 (5/24) 
  V    20.1-CSAREGVEGYT-J1.2 (1/24) 
  V    20.1-CSARPGLAGELYEQY-J2.7 (2/24) 
  V    20.1-CSARAGLAGALYEQY-J2.7 (2/24)
Day 235 PP V    8.6-CAVSDPGFKTI-J9 (11/21) 
  V    19-CALTDQQRAGNMLT-J39 (9/21) 
  V    19-CAQTDQQRAGNMLT-J39 (1/21)
V    20.1-CSAREGVEGYT-J1.2 (21/21)
PP, days after presentation off therapy.
  a    Time points were chosen based on sample availability and might not necessarily refl  ect the time when the L6M mutation fi  rst emerged.JEM VOL. 204, November 26, 2007 
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labeled allogenic T cells. These experiments indicated a sub-
stantially reduced proportion of proliferating allogenic T 
cells after exposure to MDDCs matured with B2705  –  KK10 
L6M pentamers compared with those matured in the pres-
ence of the WT pentamer (  Fig. 4 D  ). Overall, these data 
indicate that myelomonocytic binding of the B2705  –  KK10 
L6M complex can result in inhibition of DC maturation 
and function. 
DC population. This indicates that in addition to pentamers, 
HLA-B2705 complexes on the surface of live APCs can also 
mediate peptide-specifi  c inhibitory eff  ects in trans. 
  To determine if the B2705  –  KK10 L6M  –  mediated in-
hibition of DC maturation would translate into functional 
impairments of these cells, we next used MDDCs matured 
in the presence of HLA-B2705  –  KK10 WT or L6M penta-
mers to perform mixed lymphocyte reactions with CFSE-
  Figure 3.     Enhanced ILT4-mediated binding of the HLA-B2705  –  KK10 L6M complex to peripheral blood macrophages and DCs. (A) Histograms 
indicating the binding of the HLA-B2705  –  KK10 WT or KK10 L6M pentamers to macrophages, DCs, lymphocytes, or KK10-specifi  c CD8 T cell clones in the 
presence or absence of ILT4-blocking antibodies. (B) Mean fl  uorescence intensity of the respective pentamers after gating on CD14  +   macrophages  or 
CD11c  +   lin  −    HLA-DR +   DCs. Data from 10 HLA-B2705   −    chronically HIV-1  –  infected, treatment-naive subjects are shown. (C) Mean fl  uorescence intensity of 
the B2705  –  KK10 WT and L6M variant pentamers after staining with the indicated pentamer dilutions (x axis) on CD14  +   macrophages. (D) SPR sensograms 
refl  ecting the control surface  –  subtracted interactions between immobilized HLA-B27  –  KK10 L6M (top) and B27  –  KK10 WT (bottom) with recombinant ILT4. 
ILT4 was injected in fi  ve serial twofold dilutions from a starting concentration of 74     g/ml (1     M). Inset plots show nonlinear regression analysis of max-
imal responses versus concentration. One representative experiment out of three is shown.     2818 DIFFERENTIAL RECOGNITION OF CTL EPITOPE VARIANTS BY ILT4 | Lichterfeld et al.
indicate that HLA-B2705 –  KK10 L6M complexes inhibit myelo-
monocytic cell maturation and co-stimulatory molecule sur-
face expression via antigenic peptide variant-specifi  c binding 
to ILT4. 
  Frequent antigenic peptide dependency of MHC class I 
recognition by ILT4 
  In our fi  nal series of experiments, we tested whether a peptide-
specifi  c HLA class I binding to ILT4 also occurs in the con-
text of MHC class I molecules other than HLA-B2705. To 
analyze this, PBMCs from 10 chronically HIV-1  –  infected 
untreated study subjects were stained with a series of HLA-
A2, -A3, -B7, -B8, or -B40 pentamers refolded with a   variety 
of epitopic peptides derived from HIV-1, HCV, CMV, or EBV. 
  To determine whether inhibition of myelomonocytic cell 
maturation by HLA-B2705  –  KK10 L6M complexes required 
ILT4, we knocked down ILT4 expression on MDDCs using 
targeted small interfering RNA (siRNA). As shown in   Fig. 5 A  , 
an siRNA pool specifi  c for the ILT4 message, but not an 
siRNA pool specifi  c for ILT2 message, led to a substantial 
reduction in ILT4 surface expression on MDDCs.   We next 
tested whether the inhibition of DC maturation mediated by 
HLA-B2705  –  KK10 pentamers or KK10 peptide –  pulsed B2705  +   
presenting cells could be reversed by ILT4 knockout.   Fig. 5   
(B and C) shows that the inhibition of MDDC maturation by 
the HLA-B2705  –  KK10 L6M complexes either in pentamer 
form or on the surface of live APCs was abrogated by ILT4-
specifi  c siRNA in a dose-dependent fashion. Thus, these data 
  Figure 4.     Inhibition of the maturation of MDDCs by HLA-B2705  –  KK10 L6M complexes. (A and B) Histograms indicating the expression intensity 
of CD40, CD86, and HLA-DR of myelomonocytic cells after cytokine-induced maturation in the presence or absence of HLA-B2705  –  KK10 WT or B2705  –
  KK10 L6M pentamers (A) or autologous HLA-B2705  –  expressing DCs pulsed with the KK10 WT or KK10 L6M variant peptide (B). One example is shown. 
(C) Mean and standard deviation of the fl  uorescence intensity of DC maturation markers and co-stimulatory molecules after cytokine cocktail  –  mediated 
maturation in the presence or absence of the B2705  –  KK10 WT or L6M pentamers. Experiments were independently performed four times. (D) Assessment 
of HLA-B27  –  KK10 L6M  –  mediated functional inhibition of DCs by mixed lymphocyte reactions. Dot plots indicate the proportion of allogenic CD4 or CD8 T 
cells after a 6-d exposure to MDDCs in the presence of HLA-B27  –  KK10 WT or L6M pentamers. One experiment out of three in three different study sub-
jects is shown.     JEM VOL. 204, November 26, 2007 
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the interaction with innate inhibitory MHC class I receptors 
expressed on NK cells, T cells, and myelomonocytic cells. In 
this study, we show that HIV-1 mutations arising from CD8  +   
T cell  –  mediated immune pressure can substantially enhance 
the binding of viral peptide  –  MHC class I complexes to the 
inhibitory ILT4 receptor on peripheral blood monocytes and 
DCs and may, in this way, have a critical impact on their 
functional profi  le, specifi  cally with regard to their ability for 
maturation and co-stimulatory molecule up-regulation. Thus, 
our data suggest HIV-1 gene diversifi  cation leading to enhanced 
ILT4-mediated inhibition of monocyte and DC function as a 
novel mechanism of viral immune evasion. 
  Although our data clearly suggest that the interaction be-
tween ILT4 and peptide  –  MHC class I complexes occurs in 
a peptide-specifi  c fashion, it is presently unclear how this 
peptide specifi  city is mediated at the molecular level. Crystal 
structure data have indicated that the two distal extracellular 
domains (D1 and D2) of ILT2, an MHC class I  –  specifi  c in-
hibitory receptor closely related to ILT4, bind MHC class I 
molecules at the intersection of the      3 domain, which is rel-
atively conserved among diff  erent HLA alleles, and the non-
polymorphic      2 microglobulin (  35  ). Although the structural 
binding positions of ILT4 to HLA-B27 have not been identi-
fi  ed, it has been shown that ILT4 binds HLA-G also in the      
3 domain (  36  ). Yet, recent data have indicated that binding 
These experiments indicated that in the context of a shared 
HLA allele, pentamer binding intensity to CD14  +   peripheral 
blood macrophages depended dramatically on the antigenic 
peptide presented by the MHC class I complex (  Fig. 6 A  ).   
This was particularly true for HLA-A2 molecules, which 
bound strongly to macrophages when presenting the HIV-1  – 
derived YV9 epitope, but showed almost no binding when 
presenting the epitopes RV9 and IV9. Again, the binding of 
pentamers to macrophages was abrogated by ILT4 blocking 
antibodies (  Fig. 6 B  ). Pentamer binding to respective antigen-
specifi  c CD8  +   T cell populations revealed no similar diff  er-
ences in the binding intensity (not depicted), indicating that 
the observed peptide-specifi  c diff  erences between pentamer 
binding to monocytes were not due to inherent fl  uorescence 
emission characteristics of these reagents. Overall, these data 
show that the sequence of the presented antigenic peptide 
infl  uences the ILT4-mediated binding strength of HLA class I 
molecules to monocytes. 
    DISCUSSION   
  Numerous studies have indicated that HIV-1 uses its extra-
ordinary genetic fl  exibility to evade CD8  +   T cell  –  mediated 
immune responses (  12  –  19  ). Although viral escape mutations 
can directly reduce the recognition by CD8  +   T cells, almost 
nothing is known about how these viral gene alterations aff  ect 
  Figure 5.     Reversion of the HLA-B2705  –  KK10 L6M  –  mediated inhibitory effects after siRNA-induced down-regulation of ILT4. (A) Flow cyto-
metric assessment of ILT4 surface expression on MDDCs after electroporation with ILT4- or ILT2-specifi  c siRNA. (B and C) Histograms indicating the sur-
face expression of co-stimulatory molecules or DC maturation markers after exposure of ILT4 or ILT2 siRNA  –  transfected myelomonocytic cells to 
HLA-B2705  –  KK10 WT or L6M pentamers (B) or to autologous HLA-B2705  –  expressing DCs pulsed with the KK10 WT or KK10 L6M variant peptide (C). Low 
dose siRNA concentration, 0.5 nmol/million cells; high dose siRNA concentration, 1 nmol/million cells.     2820 DIFFERENTIAL RECOGNITION OF CTL EPITOPE VARIANTS BY ILT4 | Lichterfeld et al.
have suggested that immature DCs induce T cells with sup-
pressive activity upon presentation of antigen to naive T lym-
phocytes (  46  ), the maturation defect mediated by ILT4 binding 
of the B2705  –  KK10 L6M complex is likely to have important 
consequences for the functionality of T cell responses gener-
ated. Moreover, our observation strengthens previous fi  nd-
ings indicating that viruses can use the immunomodulatory 
properties of MHC class I interactions with ILT2/ILT4 as a 
means to decrease overall antiviral immune activities. For in-
stance, it has been recently shown that CMV encodes for an 
MHC class I homologue molecule with substantially  enhanced 
affi   nity to ILT2 compared with regular MHC class I  molecules, 
thus suggesting that increasing ILT2-mediated inhibitory sig-
nals might be an active viral mechanism to reduce antiviral 
immune surveillance (  47  ). Given the powerful tolerogenic ef-
fects that ILT4 can exert for the prevention of semiallogeneic 
or allogeneic cell rejection (  10  ), it is likely that increased bind-
ing between ILT4 and the HLA-B27  –  KK10 L6M complexes 
can substantially contribute to the impairment of DCs in 
chronic HIV-1 infection. However, for a complete under-
standing of the biological eff  ects of the KK10 WT and L6M 
peptides on DC function, it will be necessary to analyze how 
the KK10 WT form and its variants aff  ect recognition of HLA-
B2705 by the other myelomonocytic MHC class I receptors 
that have been described, including stimulatory receptors such 
as LIR6, which appears to have a particular capacity for recog-
nizing HLA-B2705 (  48, 49  ). 
intensities between ILT2 and a CMV-encoded HLA homo-
logue can clearly be determined by polymorphisms in the      
1 region (  37  ), which suggests that the conformation of the 
antigenic peptide-presenting      1 domain can at least indi-
rectly impact on the binding of HLA molecules to myelo-
monocytic MHC class I receptors. The peptide-dependent 
binding of peptide  –  MHC class I complexes to ILT4 shown 
here therefore similarly suggests that the structural conforma-
tion of the putative ILT4 binding site in the      3 domain of 
HLA-B27 may be shaped indirectly by the type of antigenic 
peptide presented by the MHC, or that additional inter-
actions exist between ILT4 and MHC class I molecules, po-
tentially involving the two proximal extracellular domains of 
ILT4 (D3 and D4). 
  DC dysfunction in chronic HIV-1 infection has been 
demonstrated in a variety of previous investigations, and the 
functional defects of these cells might be causally linked to the 
functional impairment of HIV-1  –  specifi  c CD8  +   T cells that 
has been reported in several previous studies (  38  –  41  ). Factors 
contributing to DC dysfunction in chronic HIV-1 infection 
include, among others, the down-modulation of co-stimulatory 
molecules by HIV-1 gene products such as vpr (  42, 43  ), the 
direct infection of DCs by HIV-1 (  44  ), and the gp120-mediated 
inhibition of IL-12 secretion by DCs (  45  ). This study extends 
these fi  ndings by showing that viral CTL escape mutations 
can lead to active suppression of DC maturation by inhibitory 
MHC class I receptors expressed on these cells. As recent data 
  Figure 6.     Peptide-dependent binding of HLA class I molecules to ILT4 on CD14  +   peripheral blood monocytes. (A) Data indicate the mean fl  uor-
escence intensity of the HLA class I pentamers refolded with the indicated epitopic peptides in 10 chronically HIV-1  –  infected, treatment-naive study subjects. 
(B) Pentamer binding in the presence (open symbols) or absence (solid symbols) of ILT4 blocking antibodies from fi  ve individuals for six epitopes is shown.    JEM VOL. 204, November 26, 2007 
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  In summary, the data presented here provide evidence that 
HIV-1 CTL escape mutations can increase recognition of pep-
tide MHC class I complexes by the inhibitory  myelomonocytic 
MHC class I receptor ILT4, and that this increase is function-
ally relevant for impairing mitogen-induced myelomonocyte 
maturation and co-stimulatory molecule up-regulation. By 
  indicating an association between CTL-mediated mutational 
escape, altered recognition by inhibitory innate immune re-
ceptors, and ensuing functional defects of professional APCs, 
these data contribute substantially to the understanding of bio-
logical events leading to and resulting from HIV-1 sequence 
evolution and will be relevant for the targeted manipulation of 
adaptive immune responses against HIV-1. 
  MATERIALS AND METHODS 
  Subjects.     HIV-1  –  infected individuals with acute, primary, or chronic HIV-1 
infection participating in this study were recruited from the Massachusetts 
General Hospital or the Fenway Community Health Care Center in Boston. 
Individuals with acute HIV-1 infection had detectable HIV-1 RNA and a 
negative HIV-1 ELISA. Primary HIV-1 infection was defi  ned by absent or 
incomplete (  <  3 bands) HIV-1 Western blot reactions and/or a documented 
HIV-1    −    test   <  1 yr before assessment. Chronically infected subjects were 
  infected for at least 3 yr and were taking no antiretroviral therapy at the time 
of study participation, unless otherwise indicated. All subjects gave written 
informed consent to participate, and the study was approved by the Massa-
chusetts General Hospital Institutional Review Board. 
  Synthetic peptides.     Peptides corresponding to described optimal HIV-1 
CD8  +   T cell epitopes and their variants (http://hiv-web.lanl.gov) were syn-
thesized at the MGH Peptide Core Facility on an automated peptide synthe-
sizer using F-moc technology. 
  ELISPOT assay.     ELISPOT assays were performed as described previously 
(  51  ). In brief, PBMCs were plated in 96-well polyvinylidene plates that had 
been precoated with 0.5     g/ml of an anti  –  human interferon-     mAb (Mabtech). 
PBMCs were added at a concentration of 100,000 cells per well in a volume 
of 100     l RPMI 1640 medium supplemented with 10% FCS, 10 mM Hepes 
buff  er,     2 mM   l-  glutamine, and 50 U/ml penicillin-streptomycin. Plates 
were incubated overnight at 37  °  C, 5% CO  2  , and developed on the next 
day as described elsewhere (  51  ). Wells containing PBMCs and medium 
with phytohemagglutinin or without any peptide were used as positive 
or negative controls, respectively, and run in triplicate on each plate. To cal-
culate the number of specifi  c T cells, the number of spots in the negative 
control wells was subtracted from the counted number of spots in each ex-
perimental well. Responses were considered positive if there were   >  50 spot-
forming cells/10  6   PBMCs and at least three times the mean number of 
spot-forming cells in the experimental wells compared with the three con-
trol wells. 
  Sorting of tetramer  +   HIV-1  –  specifi  c CD8  +   T cell populations.     Fresh 
or frozen PBMC samples were stained with PE-labeled MHC class I penta-
mers refolded with epitopic HIV-1 peptides (ProImmune) and fl  uorophore-
labeled CD8  +   antibodies, followed by decontamination with 1:100 dilution 
of fi  xation solution A (Caltag). Tetramer  +   CD8  +   cells were sorted on a 
FACS Aria cell sorter (BD Biosciences) at 70 pounds per square inch. The 
purity of sorted cell populations was consistently   >  98%. 
  TCR      and      chain sequencing.     mRNA was extracted from tetramer  +   
CD8  +   T cells using the RNeasy mini kit (QIAGEN). Anchored RT-PCR 
was then performed using a modifi  ed version of the SMART (switching 
mechanism at 5     end of RNA transcript) procedure and a TCR      or      chain 
constant region 3     primer to obtain PCR products containing the V     or      
chain in addition to the CDR3 region, the J    /     region, and the beginning 
  The physiological consequences of the increased ILT4 
binding interaction with B2705  –  KK10 L6M in vivo are likely 
to depend on the expression intensity of ILT4 on monocytes 
and DCs, and HLA class I molecules on HIV-1 target cells. 
The prominent ILT4 up-regulation during chronic HIV-1 
infection described here and elsewhere (  34  ) therefore suggests 
that ILT4-mediated inhibition of functional properties of 
APCs occurs later during the disease process, and may con-
tribute to the failure of HIV-1 patients to mount eff  ective 
pathogen-specifi  c T cell responses during the chronic phase of 
their disease. From this perspective, it appears surprising that 
we observed a de novo generation of a KK10 L6M  –  specifi  c 
CD8  +   T cell response despite immunosuppressive eff  ects re-
sulting from the interaction between the B27  –  KK10 L6M 
complex with ILT4. However, it is important to mention that 
the KK10 L6M variant seems to be highly immunogenic, and 
that there is only limited surface expression of ILT4 during 
the early stages of HIV-1 infection, at the time when the vari-
ant-specifi  c CD8  +   T cell response was generated (Fig. S1 A). 
Moreover, it is well conceivable that the ILT4-mediated 
tolerogenic functional profi  le of DCs does not abrogate their 
ability for the physical generation of new HIV-1  –  specifi  c 
CD8  +   T cells, but instead only induces a defective func-
tional profi  le of these immune responses. Indeed, dysfunctional 
HIV-1  –  specifi  c CD8  +   T cells have been repeatedly reported 
in chronic HIV-1 infection (  38, 40, 41  ), and we similarly ob-
served that the proportion of proliferating KK10 L6M/WT 
cross-reactive CD8  +   T cells in chronic infection (  n   = 3) was 
signifi  cantly lower than that of KK10 WT  –  specifi  c CD8  +   T 
cells in primary infection (  n   = 3; mean of 2 vs. 37%, P = 0.04) 
(Fig. S2). Finally, similar to other MHC class I receptors such 
as KIRs, the sequence of ILT4 can be polymorphic, and the 
identifi  ed ILT4 polymorphisms are likely to change the inter-
action with MHC class I receptors; therefore, consequences 
of increased binding of MHC class I complexes to ILT4 that 
result from CTL escape mutations will have to be evaluated in 
the context of ILT4 gene sequence alterations (  50  ). 
  The data shown here do not provide evidence for an 
  active selection of viral variants with higher binding intensity 
to ILT4, and in this way they are clearly diff  erent from HIV-1 
gene mutations leading to CD8  +   T cell escape, for which ac-
tive selection of escape variants has been documented in a 
variety of cases. The KK10 L6M variant is selected for almost 
exclusively in HLA-B27  –  expressing individuals and   therefore 
appears to be clearly related to HIV-1  –  specifi  c CD8  +   T cell  –
  mediated immune pressure. However, instead of an active 
selection of viral variants with increased binding to ILT4, it 
appears possible that the type of CTL escape mutations that 
are selected could not only depend on the structural tolerance 
of the virus and the ensuing fi  tness costs, but might also 
be infl  uenced by its eff  ects on its binding intensity to ILT4. 
Future work will therefore be necessary to assess the exact 
role that binding to ILT4 plays in shaping viral evolution and 
how peptide-specifi  c binding properties of MHC class I com-
plexes to ILT4 can be taken advantage of for the design of 
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presence of 50   μ  g/ml GM-CSF (Amgen) for 5 d in 1% human plasma 
  medium. In accordance with results reported by Ristich et al. (  11  ), ILT4 
expression was detectable on MDDCs generated in the presence of GM-CSF 
and in the absence of IL-4 (unpublished data). On day 5, immature myelo-
monocytic cells were harvested using Hanks-based Cell-disassociation buff  er 
(Invitrogen), incubated with B2705/KK10 WT or B2705/KK10 L6M pen-
tamers (ProImmune) for 4 h, and then matured using a previously described 
cocktail containing IL-1    , TNF-    , PGE-2, and IL-6 (  54  ). Alternatively, 
CFSE-labeled peptide-pulsed (60 min at 37  °  C) matured MDDCs were added 
instead of pentamers. After 16 h, matured MDDCs were harvested, stained 
with antibodies against CD83, CD40, CD80, HLA-DR, as well as CD86, 
and processed to fl  ow cytometric analysis. To calculate the relative pentamer-
mediated inhibition in the up-regulation of a specifi  c surface molecule during 
MDDC maturation, the diff  erence between the mean fl  uorescence intensity 
of that molecule in the presence or absence of the pentamer was divided by 
the diff  erence of the corresponding mean fl  uorescence intensity before and 
after maturation in the absence of pentamers. 
  Mixed lymphocyte reactions.     MDDCs generated as described above 
were matured for 16-20 h in the presence of HLA  –  B27 KK10 WT or L6M 
pentamers and then mixed with allogenic CFSE-labeled PBMCs. After 
6 consecutive days of culture in R10 medium supplemented with 10% FCS, 
10 mM Hepes buff  er,     2 mM   l-  glutamine, and 50 U/ml penicillin-strepto-
mycin, cells were stained with monoclonal CD4 and CD8 antibodies and 
processed to fl  ow cytometric analysis using a FACSCalibur instrument. 
  ILT4 knockdown.     siRNA pools specifi  c for ILT4 message (LILRB2 ON-
TARGETplus SMARTpool; Dharmacon Technologies) or ILT2 message 
(LILRB1 ON-TARGETplus SMARTpool; Dharmacon) were used at con-
centrations of 1 nmol/million cells and 0.5 nmol/million cells. MDDCs 
were harvested on day 4 of culture and washed twice with Optimem (Invit-
rogen). 10  6   MDDCs were suspended in 300 ul Optimem in the presence of 
the indicated amount of siRNA and transferred to a 4-mm electroporation 
cuvette (Bio-Rad Laboratories). Cells were left on ice for 5 min and then 
electroporated (900 V, 0.75 msec square wave; Bio-Rad Genepulser Xcell) 
and transferred back to culture medium for another 16 h before analysis. 
  SPR experiments.     To characterize the binding affi   nity between HLA  –  B27 
KK10 WT or L6M complexes and ILT4 in a cell-free system, SPR experi-
ments were performed using a BIAcore 3000 SPR instrument (BIAcore) 
in 10 mM Hepes buff  er containing 150 mM sodium chloride, 3.4 mM 
EDTA, and 0.005% (vol/vol) surfactant P-20 at 25  °  C. Recombinant HLA  –
  B27 KK10 WT or L6M tetramers (obtained from the National Institutes of 
Health [NIH]/National Institute of Allergy and Infectious Diseases tetra-
mer core facility) at a concentration of 2mg/ml in 10 mM sodium acetate, 
pH 4.6, were individually immobilized (600 resonance units) to a CM5 
sensor chip (BIAcore) using standard amine coupling methods. Toxic shock 
syndrome toxin (TSST)-1 (  55  ) in an equivalent surface density was used as 
the control surface, as there is no specifi  c binding between ILT4 and TSST-1. 
Serial twofold dilutions (74     g/ml [1       M  ] to 4.6     g/ml [62.5 nM]) of a 
recombinant protein dimer containing two extracellular domains of human 
ILT4 fused to the Fc part of human IgG (R  &  D Systems) were injected 
over the sensor chip. All of the binding experiments were performed at a 
fl  ow rate of 25     l/min, and pulses of 10 mM HCl were used to regenerate 
both surfaces between injections. After subtraction of background binding 
between ILT4 and TSST-1, the apparent binding affi   nity (  K    D  ) was de-
termined by nonlinear regression analysis of SPR responses to the various 
concentrations of injected ILT4 using the BiaEvaluation 4.1 software pro-
gram (BIAcore). 
  Proliferation assays.     PBMCs (10  6  /ml) were stained with 0.25     M CFSE 
and incubated for 6 d in the presence of the KK10 WT or L6M peptide (  38  ). 
Afterward, cells were harvested, stained with PE-labeled B2705 KK10 or 
L6M pentamers and CD8 APC antibodies, and subjected to fl  ow cytometric 
analysis using a FACSCalibur instrument. 
of the C    /     region. In brief, reverse transcription was performed at 42  °  C 
for 90 min with primers provided for the 5    -RACE reaction in a SMART-
RACE PCR kit (BD Biosciences). First and second round PCR were then 
performed using a universal 5    -end primer (5    -CTAATACGACTCAC-
TATAGGGC-3    ) and nested gene-specifi  c 3    -end primers annealing to the 
constant region of the TCR      or      chain (C     outer, GTCCATAGACCT-
CATGTCTAGCACAG; C     inner, ATACACATCAGAATCCTTAC-
TTTG; C     outer, 5    -TGTGGCCAGGCACACCAGTGTGGCC-3    ; C     
inner, 5    -GGTGTGGGAGATC-TCTGCTTCTGA-3    ). PCR reaction 
conditions were as follows: fi  rst run: 95  °  C for 30 s and 72  °  C for 2 min for 
5 cycles; 95  °  C for 30 s, 70  °  C for 30 s, and 72  °  C for 2 min for 5 cycles; and 
95  °  C for 30 s, 60  °  C for 30 s, and 72  °  C for 1 min for 25 cycles; second run: 
95  °  C for 30 s, 60  °  C for 30 s, and 72  °  C for 1 min for 30 cycles. The PCR 
product was ligated into the TOPO TA cloning vector (Invitrogen) and 
used to transform   E  s  cherichia coli   (Mach 1; Invitrogen). Colonies were se-
lected, amplifi  ed by PCR with M13 primers, and sequenced by T7 or T3 
primers on an ABI 3100 PRISM automated sequencer. Sequences were ed-
ited and aligned using Sequencher (Gene Codes Corp.) and Se-Al (University 
of Oxford, Oxford, UK) and compared with the human TCR genes data-
base (http://imgt.cines.fr/textes/IMGTrepertoire/Proteins/). The TCR V   /     
chain classifi  cation system used is that of the international ImMunoGeneTics 
database (  52  ). 
  Generation of CTL clones.     CTL clones were isolated by limiting dilution 
as described previously (  53  ) using the CD3-specifi  c mAb 12F6 as a stimulus 
for T cell proliferation. Developing clones were screened for HIV-1  –  specifi  c 
CTL activity by a chromium-51 release assay against autologous B lympho-
blastoid cell lines pulsed with the target peptide. HIV-1  –  specifi  c clones were 
maintained by stimulation every 14  –  21 d with an anti-CD3 mAb and ir-
ra  diated allogeneic PBMCs. 
  Sequencing of autologous virus.     Nested PCR for Gag on proviral DNA 
or plasma viral RNA was performed as described previously (  14  ). PCR frag-
ments were population sequenced to identify regions of sequence variation. 
All fragments were sequenced bidirectionally on an ABI 3100 PRISM auto-
mated sequencer (Applied Biosystems). If the height of the secondary peak 
at a given residue in the chromatogram was   >  25% of the dominant peak, 
a mixed base was considered present at that position. Sequencher (Gene 
Codes Corp.) and MacVector 4.1 (Oxford Molecular) were used to edit and 
align sequences. 
  Flow cytometry.     Fresh or frozen PBMCs were stained with pentamers 
(ProImmune) for 20 min at room temperature. After one wash with PBS, 
cells were incubated with PerCP-labeled CD14 antibodies or PE-Cy7  –
    labeled HLA-DR antibodies, APC-labeled CD11c antibodies, and a cocktail 
of PerCP-labeled lineage antibodies (CD3, CD8, CD14, CD56, and CD19). 
For ILT4 surface assessments, cells were stained with an ILT4-specifi  c anti-
body (clone 42D1). After 30 min of staining at room temperature, cells were 
resuspended in PBS containing 2% paraformaldehyde. Cells were acquired 
on a FACSCalibur (BD Biosciences) instrument. Compensation was per-
formed with cells stained separately with individual antibodies used in the 
test samples. To block pentamer binding, PBMCs were incubated with an 
ILT4 antibody (clone 287219; R  &  D Systems). An array of alternative anti-
bodies, including those blocking the interaction to KIR3DL1 (clone DX9; 
BioLegend) or ILT2 (clone HP-F1; provided by M. Lopez-Botet, Universi-
tat Pompeu Fabra, Barcelona, Spain) were also tested for their ability to 
block pentamer binding to cells. 
  MDDC maturation assays.     MDDC culture was performed in RPMI 
1640 medium supplemented with penicillin, streptomycin,   l-  glutamine, 
Hepes buff  er, and either 5% pooled human serum (Sigma-Aldrich) or 1% 
heparinized normal human plasma. Freshly isolated PBMCs were washed 
several times in RPMI medium to remove platelets, plated into Corning six-
well plates in 5% pooled human serum medium, and incubated for 60 min 
at 37  °  C to adhere monocytes. Adherent monocytes were propagated in the JEM VOL. 204, November 26, 2007 
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